The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Management of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) after radiological progression to first-line therapy with gefitinib.
 
Yukio Hosomi
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Yakult Honsha (Inst)
 
Chiharu Tanai
No Relationships to Disclose
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bayer; Lilly; Novartis; Takeda
 
Yasushi Goto
Consulting or Advisory Role - Boehringer Ingelheim; Lilly
Speakers' Bureau - Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Lilly (Inst); Novartis (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Yasuo Ohashi
Honoraria - Chugai Pharma
 
Hideo Kunitoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Dainippon Sumitomo Pharma; Johnson & Johnson; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takara Bio